Compare Amphastar Pharmaceuticals Inc (AMPH) vs DraftKings Inc (DKNG) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

DraftKings (DKNG) trades at $26.48, up 0.7% with neutral technical indicators. The company shows strong revenue growth, reaching $6.05B in 2025 with improving profitability, though valuation ratios remain elevated. Recent expansion into Alberta and launch of DKeX prediction platform signal growth initiatives. Analyst sentiment is bullish with 73% buy ratings and a $34.18 consensus target.

DraftKings presents growth potential through market expansion and product innovation, but faces risks from regulatory scrutiny and competitive pressures. The stock trades below analyst targets but carries high multiples, requiring sustained execution to justify valuation. Key catalysts include World Cup engagement and continued margin improvement.